
Denosumab

Technology: Denosumab is a human monoclonal antibody that binds to the RANKL protein on osteoclasts (cells that break down bone), inhibiting their formation, function, and survival, which regulates bone turnover by slowing bone resorption.

Denosumab Timeline



	Amgen v. Sandoz 1:23-cv-02406 (D.N.J.) Settled	*Amgen v. Celltrion* 1:24-cv-06497 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Samsung Bioepis* 1:24-cv-08417 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Fresenius Kabi* 1:25-cv-01080 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Accord* 1:25-cv-01305 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Hikma* 1:25-cv-12152 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Shanghai Henlius Biotech* 1:25-cv-12160 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Biocon* 1:25-cv-13358 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Dr. Reddy's* 1:25-cv-17277 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing	*Amgen v. Amneal* 1:25-cv-17278 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing	*Amgen v. Alkem* 1:25-cv-17596 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing
7,364,736	x	x	x	x	x	x	x	x	x	x	x
7,427,659		x									
7,662,930					x						x
7,888,101			x	x	x	x	x	x	x	x	x
7,928,205	x	x	x	x	x	x	x	x	x	x	x
8,053,236		x		x	x	x	x	x	x	x	x
8,058,418	x		x	x	x	x		x	x	x	x
8,217,153							x				
8,247,210			x					x			x
8,460,896		x	x	x	x	x	x	x	x	x	x
8,680,248		x	x	x	x	x	x	x	x	x	x
9,012,178	x	x	x	x	x	x		x	x	x	x
9,133,493	x				x						
9,228,168	x	x		x	x	x	x	x	x	x	x
9,320,816	x	x	x	x	x					x	
9,328,134	x	x	x	x	x	x		x	x	x	x
9,359,435	x	x	x	x	x	x	x	x	x	x	x
9,371,554						x					
9,388,447					x						
9,481,901	x		x								
10,106,829		x	x	x	x	x	x	x	x	x	x
10,167,492	x	x	x	x	x	x		x	x	x	x

	Amgen v. Sandoz 1:23-cv-02406 (D.N.J.) Settled	*Amgen v. Celltrion* 1:24-cv-06497 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Samsung Bioepis* 1:24-cv-08417 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Fresenius Kabi* 1:25-cv-01080 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Accord* 1:25-cv-01305 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Hikma* 1:25-cv-12152 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Shanghai Henlius Biotech* 1:25-cv-12160 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Biocon* 1:25-cv-13358 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Dr. Reddy's* 1:25-cv-17277 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing	*Amgen v. Amneal* 1:25-cv-17278 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing	*Amgen v. Alkem* 1:25-cv-17596 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing
10,227,627		x	x	x	x	x	x	x	x	x	x
10,421,987			x								
10,513,723	x	x	x	x	x	x	x	x	x	x	x
10,583,397	x	x	x	x	x	x	x	x	x	x	x
10,655,156			x	x	x		x	x		x	x
10,822,630	x	x	x	x	x	x		x	x	x	x
10,894,972	x	x	x	x	x	x	x	x	x	x	x
10,907,186			x					x			x
11,077,404	x	x		x	x	x	x	x	x	x	x
11,098,079	x	x	x	x	x	x	x	x	x	x	x
11,130,980	x	x	x	x	x	x		x	x	x	x
11,192,919						x	x	x	x		x
11,254,963	x	x	x	x	x	x	x	x	x	x	x
11,292,829			x								
11,299,760	x	x	x	x	x	x		x	x	x	x
11,319,568		x		x	x	x	x	x	x	x	x
11,384,378			x								
11,427,848			x								
11,434,514	x	x	x	x	x	x	x	x	x	x	x
11,459,595		x		x	x	x	x	x	x	x	x
11,486,883		x									
11,492,372						x	x	x	x		x

BIOLOGICS HQ


Spotlight On: Denosumab

VENABLE LLP

October 31, 2026

	Amgen v. Sandoz 1:23-cv-02406 (D.N.J.) Settled	*Amgen v. Celltrion* 1:24-cv-06497 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Samsung Bioepis* 1:24-cv-08417 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Fresenius Kabi* 1:25-cv-01080 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Accord* 1:25-cv-01305 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Hikma* 1:25-cv-12152 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Shanghai Henlius Biotech* 1:25-cv-12160 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Biocon* 1:25-cv-13358 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Settled	*Amgen v. Dr. Reddy's* 1:25-cv-17277 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing	*Amgen v. Amneal* 1:25-cv-17278 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing	*Amgen v. Alkem* 1:25-cv-17596 (D.N.J.) / MDL 1:25-md-03138 (D.N.J.) Ongoing
11,634,476			x								
11,685,772			x								
11,744,950			x	x							
11,786,866				x							
11,946,085		x	x	x	x	x	x	x	x	x	x
11,952,605		x		x	x	x	x	x	x	x	x
12,084,686				x	x	x	x	x	x	x	x


BPCIA and Denosumab Litigation Status



VENABLE LLP

*BPCIA Litigations includes Denosumab Litigations.

Denosumab Challenged Claim Types in Litigation*



*Litigation Defendants alleged to infringe at least these claims in complaints/amended complaints.

VENABLE LLP